Patent SG-11201810658P-A (SG)
Title: Methods for treating heterotopic ossification
Inventor: DESJARDINS CLARISSA
IPC: A61P3/00
Filed: 2017-06-08
Abstract: FIGA FIG. 3B 13,090 0 16,000 14,000 WOO 0 10,000 8,000 8,000 E LOGO 1,009 nano( Placebo/ Untreated PVD .• Ouleicent PV0 PVC PVC Non-QL escentonly Quiescent/ Non-Quiescent Only 10/5 mg Non-Quiescent 2010 mg 11,01X1 16„000 0 2 E E E 4,16 1 7i me. 413 mrtv su 4 7 • 14 0 10,731mm , 212 Me 4 . 1-10 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 December 2017 (14.12.2017) WIPO I PCT (51) International Patent Classification: A61K 31/415 (2006.01) A61P 3/00 (2006.01) A61K 31/44 (2006.01) CO7D 213/30 (2006.01) A61K 31/519 (2006.01) CO7D 231/12 (2006.01) A61P 19/04 (2006.01) CO7D 487/04 (2006.01) (21) International Application Number: PCT/CA2017/050701 (22) International Filing Date: 08 June 2017 (08.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/347,381 08 June 2016 (08.06.2016) US (71) Applicant: CLEMENTIA PHARMACEUTICALS INC. [CA/CA]; Suite 550, 4150 Ste-Catherine Street West, Montreal, Quebec H3Z 2Y5, Canada. (CA). (72) Inventors: DESJARDINS, Clarissa; 118 Aberdeen, West- mount, Quebec H3Y 3A7 (CA). GROGAN, Donna Roy; 56 Dwight St., #2, Boston, Massachusetts 02118-3609 (US). PACKMAN, Jeffrey Neal; 240 Country Dr., West- on, Massachusetts 02493-1138 (US). HARNETT, Mark; 141 Whitman St., Stow, Massachusetts 01775 (US). (74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.; 40th Floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) = (54) Title: METHODS FOR TREATING HETEROTOPIC OSSIFICATION (57) : The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare- ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva. ill~~~~~~~~ 011101tIIl DIDu IDIIIolDIDIIIIImiEl0II111111 0IIIIII (10) International Publication Number WO 2017/210792 Al W O 20 17 / 2107 9 2 Al